To read more on this topic click here.
Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs
Author: Simge Eva DoganPublished: 7 November 2018
Prep: Cook: Serves:
Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions.
The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year.
Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising programs.”
For more information on Parkinson’s treatments please visit the EPDA website
Share this story
‘Chopsticks are not easy for a person with Parkinson’s’
In the third in our series on this year’s World Parkinson Congress (WPC),READ MORE
Parkinson’s and depression: it’s not all in your mind
The causes of and treatments for depression and Parkinson’s diseaseREAD MORE
How New York inspired Copenhagen to walk for Parkinson’s
‘Exercise is medicine’: the Danish Parkinson’s Association’s mottoREAD MORE